Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Net Margin (2016 - 2025)

Cardiff Oncology's Net Margin history spans 15 years, with the latest figure at 2972.43% for Q4 2025.

  • For Q4 2025, Net Margin rose 483751.0% year-over-year to 2972.43%; the TTM value through Dec 2025 reached 7736.26%, down 109079.0%, while the annual FY2025 figure was 7736.26%, 108106.0% down from the prior year.
  • Net Margin for Q4 2025 was 2972.43% at Cardiff Oncology, up from 9386.67% in the prior quarter.
  • Across five years, Net Margin topped out at 2972.43% in Q4 2025 and bottomed at 14863.51% in Q1 2022.
  • The 5-year median for Net Margin is 7927.64% (2024), against an average of 8737.44%.
  • The largest annual shift saw Net Margin tumbled -766212bps in 2022 before it soared 864257bps in 2024.
  • A 5-year view of Net Margin shows it stood at 7103.76% in 2021, then grew by 4bps to 6799.22% in 2022, then increased by 12bps to 5989.1% in 2023, then tumbled by -30bps to 7809.93% in 2024, then skyrocketed by 62bps to 2972.43% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Net Margin are 2972.43% (Q4 2025), 9386.67% (Q3 2025), and 11528.1% (Q2 2025).